HLS Therapeutics Inc.
HLS
Kedudukan dalam Saham
#21880
HLS Therapeutics Inc. operates as a specialized pharmaceutical firm,... HLS Therapeutics Inc. operates as a specialized pharmaceutical firm, concentrating on the acquisition and commercialization of medicinal products, primarily within the niche central nervous system (CNS) and cardiovascular (CV) sectors. Its reach extends across Canada, the United States, and international markets. The company's core product lineup includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsule formulation; and PERSERIS, an injectable risperidone product for treating schizophrenia. Additionally, HLS offers MyCare psychiatry laboratory assays and MyCare Insite tests for point-of-care therapeutic drug-level monitoring. Furthermore, the company possesses U.S. marketing privileges for Absorica, a commercial-stage dermatology solution, and Canadian rights for Trinomia, a cardiovascular therapeutic. It also manages a portfolio of royalty interests from four distinct healthcare products. Founded in 2018, HLS Therapeutics Inc. is based in Etobicoke, Canada.
Harga Saham
$3.05
Modal Pasaran
$94.22M
Perubahan (1 hari)
1.47%
Perubahan (1 tahun)
-24.23%
Negara
CA
Perdagangan HLS Therapeutics Inc. (HLS)
Kategori
Healthcare
Bilangan saham terbitan bagi HLS Therapeutics Inc. (HLS)
Bilangan saham terbitan setakat October 2026: 0
Menurut laporan kewangan terkini dan harga saham HLS Therapeutics Inc., bilangan saham terbitan semasa ialah 0. Pada akhir October 2026, syarikat mempunyai 0 saham terbitan. Bilangan saham terbitan biasanya dipengaruhi oleh pecahan saham dan pembelian balik saham.
Sejarah saham terbitan untuk HLS Therapeutics Inc. (HLS) dari 2026 hingga 2026
Saham terbitan pada akhir setiap tahun
| Tahun | Saham Terbitan | Ubah |
|---|---|---|
| Tidak cukup data untuk tarikh yang disediakan. | ||
Saham terbitan bagi syarikat atau pesaing yang serupa
| Syarikat | Saham Terbitan | Perbezaan | Negara |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 2.40B | - |
IN
|
